Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT01652482 - Cetuximab + FOLFIRI vs Duligotuzumab + FOLFIRI & Colorectal Cancer (CRC) (KRAS wild-type)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Duligotuzumab + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer.

Primary outcome measures:
Progression-free Survival (PFS)

The authors' conclusion was: Duligotuzumab plus FOLFIRI did not appear to improve the outcomes in patients with RAS exon 2/3 wildtype mCRC compared with cetuximab + FOLFIRI.
Hill et al. 2018 Clin Cancer Res. 24(10): 2276-2284…

References (Sources)

Cancer Therapy: Clinical Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RASWild-Type Metastatic CRC
Hill et al. 2018 Clin Cancer Res. 24(10): 2276-2284

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

NCT01652482 - Cetuximab + FOLFIRI vs Duligotuzumab + FOLFIRI & Colorectal Cancer (CRC) (KRAS wild-type)

Welcome to meRfi Microbiome!

Contents

References (Sources)

AI Chat

Links